查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
中枢神经系统药物市场 2022-2028
市场调查报告书
商品编码
1215776

中枢神经系统药物市场 2022-2028

Central Nervous System Therapeutic Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3个工作天内

价格

在预测期内，全球中枢神经系统治疗市场预计将以 7.5% 的复合年增长率增长。 全球神经系统疾病患病率上升导致中枢神经系统治疗全球市场增长率加快。 根据世界卫生组织 (WHO) 的数据，全世界有超过 5000 万人患有癫痫症。 此外，据估计全世界有4750万痴呆症患者，每年有770万人新诊断为痴呆症。 阿尔茨海默氏病是痴呆症最常见的原因，据信占 60-70% 的病例。 此外，全世界偏头痛的患病率超过 10%。 这正在加速对这些疾病治疗的需求并推动市场增长。

全球中枢神经系统治疗市场根据适应症、用途和药物类别进行细分。 根据适应症，市场分为神经血管疾病、中枢神经系统创伤、心理健康、神经退行性疾□□病、传染病、癌症等。 按用途分为医院/诊所、家庭医疗和其他。 按药物类别，市场分为免疫调节剂、干扰素、脱羧□抑製剂、多巴胺激动剂、抗抑郁药等。 以上分区可根据您的要求定制。 免疫调节剂用于抑制免疫系统并帮助身体抵抗感染、癌症和其他疾病。

内容

第 1 章报告概述

  • 当前行业分析和增长前景
  • 全球中枢神经系统药物市场的复苏情景
  • 研究方法和工具
  • 市场细分
    • 按细分
    • 按地区

第 2 章市场概述和洞察

  • 调查范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 推荐
    • 总结

第三章竞争格局

  • 主要公司分析
    • 强生服务公司
    • 默克公司
    • 诺华公司
    • 百健公司
    • 礼来公司
  • 关键策略分析

第四章市场细分

  • 全球中枢神经系统药物市场：按适应症分类
    • 神经血管疾病
    • 中枢神经系统创伤
    • 心理健康
    • 神经退行性疾□□病
    • 感染
    • 癌症
  • 全球中枢神经系统药物市场：按应用分类
    • 医院和诊所
    • 家庭护理
    • 其他
  • 全球中枢神经系统药物市场：按药物类别分类
    • 免疫调节剂
    • 干扰素
    • 脱羧□抑製剂
    • 多巴胺激动剂
    • 抗抑郁药
    • 其他

第五章区域分析

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 意大利
    • 西班牙
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 世界其他地方

第六章公司简介

  • AstraZeneca plc
  • Cipla Ltd.
  • CNS Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Lupin Ltd.
  • Medopharm Private Ltd.
  • Neurelis, Inc.
  • Nuventra Pharma Sciences
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Shire plc
  • Teva Pharmaceutical Industries Ltd.
Product Code: OMR2026832

Title:Global Central Nervous System Therapeutic Market Size, Share and Trends Analysis Report, By Indication (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, and Cancer), By Application (Hospital and Clinic, Homecare, and Others), By Drug Class (Immunomodulatory Drugs, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Antidepressants, and Others), Forecast Period (2022-2028).

The global central nervous system therapeutics market is anticipated to grow at a CAGR of 7.5% during the forecast period. The rising prevalence of neurological disorders across the globe is leading to the increasing growth of the global central nervous system therapeutic market. According to the World Health Organization (WHO), over 50 million people have epilepsy globally. It is estimated that there are globally 47.5 million people with dementia with 7.7 million new cases every year. Alzheimer's disease is the most common cause of dementia and may contribute to 60-70% of cases. The prevalence of migraine is more than 10% across the globe. This, in turn, is accelerating the demand for the treatment of these conditions, thereby driving market growth.

The global central nervous system therapeutics market is segmented based on indication, application, and drug class. Based on the indication, the market is segmented into neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, and cancer. Based on the application, the market is segmented into hospitals & clinics, homecare, and others. Based on drug class, the market is segmented into immunomodulatory drugs, interferons, decarboxylase inhibitors, dopamine agonists, antidepressants, and others. The above-mentioned segments can be customized as per the requirements. Immunomodulatory drugs are used as it suppresses the immune system and supports the body to fight infection, cancer and other diseases.

The global central nervous system therapeutic market is segmented based on geography including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa and Latin America). The market can be analyzed for a particular region or country level as per the requirement. North American region is expected to hold a significant share in the global CNS therapeutic market, owing to the rising incidence of neurodegenerative disorders such as brain tumor in the region. According to the American Cancer Society, latest data in 2022 around 25,050 malignant tumors of the brain or spinal cord will be diagnosed in the US and around 18,280 people will die from the brain and spinal cord tumors.

The major companies serving the global central nervous system therapeutic market include Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Biogen Inc., and Eli Lilly, and Company Inc. The market players are contributing to the market growth through the adoption of various strategies including mergers and acquisitions, collaborations, and new product launches, to stay competitive in the market. For instance, in May 2022, Biogen Inc. and Denali Therapeutics Inc. announced the initiation of phase 2b study of LRRK2 Inhibitor in Parkinson's Disease which is a central nervous disease that will slow down the progression of Parkinson's disease.

Research Methodology

The market study of the global central nervous system therapeutic market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Central Nervous System Therapeutic Market Research and Analysis by Indication
  • Global Central Nervous System Therapeutic Market Research and Analysis by Application
  • Global Central Nervous System Therapeutic Market Research and Analysis by Drug Class

The Report Covers:

  • Comprehensive research methodology of the global central nervous system therapeutic market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global central nervous system therapeutic market.
  • Insights about market determinants that are stimulating the global central nervous system therapeutic market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Recovery Scenario of Global Central Nervous System Therapeutic Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Johnson & Johnson Services Inc.
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. Merck & Co. Inc.
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Novartis AG
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Biogen Inc.
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
    • 3.1.5. Eli Lilly and Company Inc.
      • 3.1.5.1. Overview
      • 3.1.5.2. Financial Analysis
      • 3.1.5.3. SWOT Analysis
      • 3.1.5.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Central Nervous System Therapeutics Market by Indication
    • 4.1.1. Neurovascular Diseases
    • 4.1.2. CNS Trauma
    • 4.1.3. Mental Health
    • 4.1.4. Neurodegenerative Diseases
    • 4.1.5. Infectious Diseases
    • 4.1.6. Cancer
  • 4.2. Global Central Nervous System Therapeutic Market by Application
    • 4.2.1. Hospitals and Clinics
    • 4.2.2. Homecare
    • 4.2.3. Others
  • 4.3. Global Central Nervous System Therapeutic Market by Drug Class
    • 4.3.1. Immunomodulatory Drugs
    • 4.3.2. Interferons
    • 4.3.3. Decarboxylase Inhibitors
    • 4.3.4. Dopamine Agonists
    • 4.3.5. Antidepressants
    • 4.3.6. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AstraZeneca plc
  • 6.2. Cipla Ltd.
  • 6.3. CNS Pharmaceuticals, Inc.
  • 6.4. F. Hoffmann-La Roche Ltd.
  • 6.5. GlaxoSmithKline plc
  • 6.6. H. Lundbeck A/S
  • 6.7. Lupin Ltd.
  • 6.8. Medopharm Private Ltd.
  • 6.9. Neurelis, Inc.
  • 6.10. Nuventra Pharma Sciences
  • 6.11. Otsuka Pharmaceutical Co., Ltd.
  • 6.12. Pfizer Inc.
  • 6.13. Sanofi S.A.
  • 6.14. Shire plc
  • 6.15. Teva Pharmaceutical Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEUROVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CNS TRAUMA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR MENTAL HEALTH MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEURODEGENERATIVE DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOMECARE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 13. GLOBAL IMMUNOMODULATORY DRUGS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL INTERFERONS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBAL DECARBOXYLASE INHIBITORS CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 16. GLOBAL DOPAMINE AGONISTS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 17. GLOBAL ANTIDEPRESSANTS CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 18. GLOBAL OTHER DRUG CLASS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 19. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 20. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 21. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 22. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 23. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 24. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 25. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 26. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 27. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 28. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 29. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 30. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 31. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 32. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 33. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 34. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 35. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)

 

LIST OF FIGURES

  • 1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEURODEGENERATIVE DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY INDICATION, 2021 VS 2028 (%)
  • 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEUROVASCULAR DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CNS TRAUMA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR MENTAL HEALTH MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEURODEGENERATIVE DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR INFECTIOUS DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOSPITAL & CLINIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOMECARE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR OTHERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY DRUG CLASS, 2021 VS 2028 (%)
  • 14. GLOBAL IMMUNOMODULATORY DRUGS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. GLOBAL INTERFERONS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 16. GLOBAL DECARBOXYLASE INHIBITORS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 17. GLOBAL DOPAMINE AGONISTS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 18. GLOBAL ANTIDEPRESSANTS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 19. GLOBAL OTHER DRUG CLASS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 20. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 21. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. UK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. REST OF EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 31. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 32. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 33. REST OF ASIA-PACIFIC CENTRAL NERVOUS SYSTEMTHERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 34. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)